GlaxoSmithKline GSK's new CEO Walmsley paid 25% less than predecessor Witty GlaxoSmithKline (GSK) has confirmed rumours that its incoming CEO Emma Walmsley will be paid less than her predecessor, Sir Andrew Witty.
News BMS appoints new science chief in fall-out from Opdivo setba... Bristol-Myers Squibb’s (BMS) chief scientific officer Francis Cuss is to step down following the company's huge lung cancer setback with Opdivo last year, to be replaced by former Massachus
News Pfizer and Merck's diabetes contender looks to challenge Jar... Merck and Pfizer have Boehringer and Lilly in their sights with ertugliflozin
News Blow for MSD as NICE rejects Keytruda in first line lung can... Firm will have to offer further discount to get drug to NHS patients.
News Merck's failure casts gloom over remaining BACE Alzheimer's ... But trial in patients in early stage of the disease continues.
News Opdivo still clear immunotherapy leader despite Keytruda gai... Immunotherapy takes on rivals from Roche and BMS.
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.